Dr. Xingxiang Pu 蒲兴祥
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Lung cancer (adenocarcinoma, squamous cell carcinoma, small cell), lung nodules, melanoma, gastric, colon, and rectal cancers, and tumors of unknown or multiple primary sites.
Dr. Pu holds a doctorate in oncology and serves as Chief Physician at Hunan Cancer Hospital. A former visiting scholar at MD Anderson Cancer Center, Dr. Pu has over 20 years of experience in clinical care, research, and teaching for lung, gastrointestinal, and melanoma tumors. Dr. Pu has published over 50 papers, including more than 20 SCI articles as first or co-first author.
Professional roles
- Standing Committee Member, Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Melanoma Expert Committee, China Anti-Cancer Association
- Vice Chair, Melanoma Professional Committee, Hunan Anti-Cancer Association
- Reviewer, Oncotarget and Journal of Cancer Research Updates
Name order: in Chinese the family name comes first (Pu Xingxiang). Papers usually list the name as Xingxiang Pu or Pu X.
Selected publications
77 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Lung Cancer Res, 2025 (senior author): Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort study. PubMed 41510384
- Adv Ther, 2025 (first author): Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials. PubMed 40354010
- Thorac Cancer, 2025 (first author): Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives. PubMed 40551477
- Biol Direct, 2024 (senior author): ADAMTS4 exacerbates lung cancer progression via regulating c-Myc protein stability and activating MAPK signaling pathway. PubMed 39415271
- Am J Clin Oncol, 2024 (senior author): The microRNA-34 Family and Its Functional Role in Lung Cancer. PubMed 38700126
- Lung Cancer, 2024 (first author): Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial. PubMed 38552544
- EClinicalMedicine, 2024 (first author): Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. PubMed 38261958
- Future Oncol, 2024 (first author): Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. PubMed 39360943
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion